Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Phase III Study Assessing the Efficacy Safety and Immunogenicity of SOK583A1 Versus Eylea in Patients With Neovascular Age-related Macular Degeneration

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary

  • 0 views
  • 17 Jul, 2021
  • 38 locations
Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea in Subjects With Wet Age-related Macular Degeneration

RBM-007 injections in combination with Eylea dosed at every other month, compared to Eylea monotherapy dosed at every other month in approximately eighty-one subjects with exudative age-related

age-related macular degeneration
optical coherence tomography
spectral domain optical coherence tomography
edema
macular edema
  • 17 views
  • 06 Jul, 2021
  • 8 locations
The Sahlgrenska Anti-VEGF Study

injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea). The study also aims to evaluate if there is a difference in best

  • 0 views
  • 04 Feb, 2021
  • 1 location
Extension Study of MYL-1701P-3001 for Safety and Efficacy

This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 study.

  • 0 views
  • 27 May, 2021
  • 13 locations
A Study to Comparing SCD411 and Eylea in Subjects With Wet Age-related Macular Degeneration (AMD)

prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea (aflibercept), an anti-VEGF drug. The study aims to prove

  • 0 views
  • 27 Jan, 2021
  • 76 locations
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea ) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea) in the treatment of neovascular age-related macular degeneration. Subjects will be

  • 57 views
  • 14 Jul, 2021
  • 222 locations
Study to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensitive Lining Inside the Eye

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age

  • 0 views
  • 09 Jul, 2021
  • 310 locations
BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Diabetic macular edema degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management

edema
diabetic macular edema
macular edema
eylea
  • 0 views
  • 18 Jul, 2021
  • 1 location
BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management

  • 0 views
  • 24 May, 2021
  • 1 location